| __timestamp | Teva Pharmaceutical Industries Limited | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5078000000 | 13774000 |
| Thursday, January 1, 2015 | 4717000000 | 22479000 |
| Friday, January 1, 2016 | 5096000000 | 27388000 |
| Sunday, January 1, 2017 | 4986000000 | 35610000 |
| Monday, January 1, 2018 | 4214000000 | 49007000 |
| Tuesday, January 1, 2019 | 3806000000 | 61139000 |
| Wednesday, January 1, 2020 | 3671000000 | 68836000 |
| Friday, January 1, 2021 | 3528000000 | 97592000 |
| Saturday, January 1, 2022 | 3445000000 | 106903000 |
| Sunday, January 1, 2023 | 3498000000 | 120998000 |
| Monday, January 1, 2024 | 3702000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Teva Pharmaceutical Industries Limited and Vericel Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses.
Teva, a global leader, has seen its SG&A expenses decline by approximately 31% from 2014 to 2023. This reduction reflects strategic cost management amidst industry challenges. Notably, Teva's expenses peaked in 2016, followed by a consistent downward trend, reaching their lowest in 2022.
Conversely, Vericel, a burgeoning player, experienced a staggering 780% increase in SG&A expenses over the same period. This surge underscores Vericel's aggressive expansion and investment in growth, with expenses climbing steadily each year.
These insights reveal the diverse strategies of established and emerging pharmaceutical companies in navigating operational costs.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights